Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch... see more

TSX:SVA - Post Discussion

Sernova Corp > no exogenous insulin supplementation???
View:
Post by 88STR8T on Aug 10, 2020 9:25pm

no exogenous insulin supplementation???

i was surprised to read this in the Echelon report.... it is not something I remember reading anywhere or that Sernova has publicly announced this fact. Has anyone read this anywhere else?
I think this would be very big news....

we are primarily focused in the near-term on patient outcomes in the University of Chicago-based clinical trial for which early patient outcomes (sustainability of blood glucose homeostasis post-Cell Pouch implantation without exogenous insulin supplementation has been observe in early cases) have been highly encouraging
Comment by Sonny7 on Aug 10, 2020 10:16pm
Good one 88. There is that tendency to ignore things that you don’t immediately understand but you shamed me into some mini research.  Yes, in my non medical or science background and from what I recently read I would say that it is highly desirable. My interpretation being that with the cell pouch vascularized and islets in place is showing results as intended with insulin producing islets ...more  
Comment by elgin1 on Aug 10, 2020 10:47pm
Well that saying no insulin required comment by Echelon is very significant . The question is why has not management communicated this to the public ? Or was this Loe over reaching ? A news release on that statement alone would be a game changer but management is so inept or feeble they can barely write a news release .  Did anybody notice almost all the volume today traded was between Rbc ? ...more  
Comment by BioTeck on Aug 10, 2020 11:43pm
Go look at the corporate presentation on the website which shows the reduction of insulin. It wasn't very much at all. Echelon report says early, perhaps the pouch starts off reducing but then tapers off or Lowe is out to lunch. Don't get too jazzed folks, there is a reason we are trading where we are....no deal means stagnant share price. No deal also means pharma is not seriously ...more  
Comment by Redbaron2211 on Aug 11, 2020 12:10am
I have to agree with Bio the only reason they use Insulin is because it takes time to figure out the dosing, they need to use small doses as they hone it in.  Last fall the NR measuring C-petide says it all it's been confirmed that islets are abundant and highly vascularized surviving long term producing insulin.  Now it's just a matter of getting quantity right and ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities